Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and FMB Research’s Franklin Berger. Other undisclosed private investors also participated.

Rain co-founder, CEO and Chairman Avanish

Read the full 477 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE